Emily M. Meara

Emily M. Meara

Auto-generated profile, based on publicly available information

Emily M. Meara

Department of Dermatology, Brigham and Women’s Hospital

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
EHEdward P. Harvey
Edward P. Harvey
JSJeffrey S Smith
Jeffrey S Smith
JHJoseph D. Hurley
Joseph D. Hurley
AGAlyana Granados
Alyana Granados
ESErnst W. Schmid
Ernst W. Schmid
KSKatherine J. Susa
Katherine J. Susa
Antibodies are central mediators of the adaptive immune response, and they are powerful research tools and therapeutics. Antibody discovery requires substantial experimental effort, such as immunization campaigns or in vitro library screening. Predicting antibody-antigen binding a priori remains challenging. However, recent machine learning methods raise the possibility of in silico antibody discovery, bypassing or reducing initial experimental bottlenecks. Here, we report a virtual screen using AlphaFold-Multimer (AF-M) that prospectively identified nanobody binders to MRGPRX2, a G protein-coupled receptor (GPCR) and therapeutic target for the treatment of pseudoallergic inflammation and itch. Using previously reported nanobody-GPCR structures, we identified a set of AF-M outputs that effectively discriminate between interacting and non-interacting nanobody-GPCR pairs. We used these outputs to perform a prospective in silico screen, identified nanobodies that bind MRGPRX2 with high affinity, and confirmed activity in signaling and functional cellular assays. Our results provide a proof of concept for fully computational antibody discovery pipelines that can circumvent laboratory experiments.

23 April 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
EHEdward P. Harvey
Edward P. Harvey
JSJeffrey S Smith
Jeffrey S Smith
JHJoseph D. Hurley
Joseph D. Hurley
AGAlyana J. Granados
Alyana J. Granados
ESErnst W. Schmid
Ernst W. Schmid
KSKatherine J. Susa
Katherine J. Susa
Antibodies are central mediators of the adaptive immune response, and they are powerful research tools and therapeutics. Antibody discovery requires substantial experimental effort, such as immunization campaigns or in vitro library screening. Predicting antibody-antigen binding a priori remains challenging. However, recent machine learning methods raise the possibility of in silico antibody discovery, bypassing or reducing initial experimental bottlenecks. Here, we report a virtual screen using AlphaFold-Multimer (AF-M) that prospectively identified nanobody binders to MRGPRX2, a G protein-coupled receptor (GPCR) and therapeutic target for the treatment of pseudoallergic inflammation and itch. Using previously reported nanobody-GPCR structures, we identified a set of AF-M outputs that effectively discriminate between interacting and non-interacting nanobody-GPCR pairs. We used these outputs to perform a prospective in silico screen, identified nanobodies that bind MRGPRX2 with high affinity, and confirmed activity in signaling and functional cellular assays. Our results provide a proof of concept for fully computational antibody discovery pipelines that can circumvent laboratory experiments.

30 October 2025 in Pediatric Dermatology
Verified
Journal Article
Closed access
EMEmily M. Meara
Emily M. Meara
RARichard J. Antaya
Richard J. Antaya

21 May 2025 in medRxiv
Verified
Preprint
Open access
PDF file
EMEmily M. Meara
Emily M. Meara
VNVinod E. Nambudiri
Vinod E. Nambudiri
JSJeffrey S Smith
Jeffrey S Smith
Skin biopsies are heavily relied upon in dermatology to diagnose cutaneous malignancies. Mastering skin biopsies and recognizing skin cancer is a core component of dermatology residency training. However, limited data exists on evaluative standards for biopsy training and residents’ accuracy in diagnosing skin cancer. This study aimed to analyze pre- and post-biopsy diagnostic accuracy of a second-year resident in the Harvard Combined Dermatology Residency Program from July 2021 to June 2022. This resident recorded biopsies performed in specialty dermatology clinics across three large academic centers with attending oversight and the hypothesized pre-biopsy diagnosis and the subsequent histopathologically confirmed diagnosis. Stratifying lesions into categories of squamous cell carcinoma (SCC), basal cell carcinoma (BCC), and benign and subsequently comparing the recorded pre- and post-biopsy diagnoses, it was determined that this resident correctly identified the diagnosis in 64% of the cases and correctly diagnosed all histologically confirmed skin cancers as SCC or BCC. The specificity of this resident in identifying an SCC or BCC was 56%. This study provides a preliminary foundational dataset for developing evidence-based residency training guidelines to better prepare residents for independent clinical practice. It serves as a model for providing trainees and programs with information on variations in practice patterns.

20 August 2025 in Pediatric Dermatology
Verified
Journal Article
Closed access
EMEmily M. Meara
Emily M. Meara
DCDorothy L. Curran
Dorothy L. Curran
KWKaren Wiss
Karen Wiss
IPIsabella Plumptre
Isabella Plumptre

2 April 2026 in Pediatric Dermatology
Verified
Journal Article
Closed access
EMEmily M. Meara
Emily M. Meara
DMDaniela Guerrero Mullix
Daniela Guerrero Mullix
JPJuan Putra
Juan Putra
HPHoracio Padua
Horacio Padua
JMJohn B. Mulliken
John B. Mulliken
DBDaniel M. Balkin
Daniel M. Balkin